# Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway

> **NCT07649629** · — · RECRUITING · sponsor: **Regina Elena Cancer Institute** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DIAGNOSTIC_TEST:** Plasma-based liquid biopsy

## Key facts

- **NCT ID:** NCT07649629
- **Lead sponsor:** Regina Elena Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649629, "Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*